42 results about "Neural Tissue Damage" patented technology

A method for treating a degenerative or traumatic injury to a nerve tissue or the brain by administering at or near the injury site a composition containing adherent bone marrow stem cells suspended in a pharmaceutically acceptable liquid in an amount effective to elicit axonal regeneration or re-myelination at the site of injury.

The invention discloses an intervertebral foramen puncture guide device which comprises a vertical positioning device, a horizontal adjusting device and an angle adjusting device, wherein the vertical positioning device is connected with the horizontal adjusting device by a longitudinal-transverse rod connector; the angle adjusting device is connected with the horizontal adjusting device; an intervertebral foramen puncture sleeve is fixed on the angle adjusting device; and an intervertebral foramen puncture needle penetrates in the intervertebral foramen puncture sleeve. In the invention, based on the principle that two points define a straight line and through the guide of a zygopophysis puncture needle and the intervertebral foramen puncture needle sleeve, accurate intervertebral foramen puncture can be realized conveniently, accurately and quickly; only a little and simple X perspective is needed during the operation, and thus the ray exposure of the medical personnel and patients is reduced; and due to the guide of the zygopophysis puncture needle, the puncture blindness is avoided, the risk of vascular nerve tissue damage is reduced, the puncture accuracy and safety are guaranteed, the operation time is shortened, the device is easy to learn and understand, the learning period is shortened, and the efficiency is improved.

The invention provides novel pyridines, pharmaceutical compositions comprising such pyridines, and the use of such compositions in treating injured mammalian nerve tissue, including but not limited to an injured spinal cord. In one embodiment, the compounds, compositions, and methods of the instant invention treat a mammalian nerve tissue injury by restoring action potential or nerve impulse conduction through a nerve tissue lesion. Significantly, in vivo application of compounds of the instant invention established, on the basis of SSEP testing, that the compounds provide longer lasting effects at lower concentrations than comparable treatment with the known agent 4-aminopyridine (4 AP).

A composite nerve conduit comprising an elongated body comprising one or more hollow elongated internal channels for guiding and promoting nerve regeneration. The conduit is a three-dimensional scaffold comprising a crosslinked hybrid/composite matrix of collagen and soy protein isolate having improved mechanical and biocompatibility properties. Methods of using the conduit for promoting nerve regeneration at a site of neural tissue damage by bridging wounded, severed, or damaged nerve sections in a peripheral and/or central nervous system. Methods of fabricating composite neural conduits are also disclosed.

The invention discloses a plaster for treating cervical spondylosis and lumbar spondylosis and belongs to the technical field of plaster preparations. The plaster comprises a vector (1), an outer plaster (2) and an inner plaster (3), wherein the inner plaster (3) is arranged between the outer plaster (2) and the vector (1); the coating area of the outer plaster (2) is greater than that of the inner plaster (3); a coating region of an inner plaster body is positioned inside a plaster coating region of the outer plaster (2). The plaster can be used for effectively treating spondylodynia, repairing connective tissue and nerve tissue damages caused by spondylodynia and relieving spinal disease complications, and the plaster is low in allergic rate and does not mould and lose the pharmacological effect after being stored for a long period of time. According to the preparation method of the plaster, the plaster is purified by adopting an oil-soaking extraction mode or an ethyl alcohol and water mixed liquor extraction mode, and the obtained outer plaster can have the effects of preventing corrosion, inhibiting bacteria, resisting allergy and preventing the inner plaster from being aired and crushed.

The invention discloses applications of L-serine or medicinal salts thereof in preparing medicaments used for preventing and treating brain injuries and nerve tissue injuries. The research finds that the L-serine is capable of significantly improving the neural functional grade of a mouse with traumatic brain injuries, reducing brain tissue loss after being injured, alleviating hippocampal neuron neuronal degeneration and necrosis significantly, and improving learning and memory functions. The applications of the L-serine as a nerve protection medicine in treating acute injuries caused by the brain injuries are disclosed for the first time.

It is intended to provide an animal model of urinary dysfunction induced by damage in brain nerve tissue in a small animal conveniently and at a high reproducibility. A rat in which the central urinary function alone is specifically damaged by regionally injuring the brain superior colliculus with the use of a legion generator. The animal model of urinary dysfunction is useful in a method of screening a therapeutic agent for urinary dysfunction.

The invention discloses a nerve stimulator circuit based on rapid charge balance in a mixed mode. The nerve stimulator circuit comprises a main stimulation part, an electrode short-connecting part anda short current pulse part, the main stimulation part comprises a current source and n pairs of output switches, and each pair of output switches corresponds to an electrode; the electrode short-connecting part comprises n short-connecting switches; and the short current pulse part comprises a window comparator, a control unit, a compensating current unit and n pairs of selective switches, each pair of selective switches corresponds to an electrode, the voltage difference on the electrodes is monitored and compared with safety voltage VW, the output end of the window comparator is connected with the control unit, if the voltage difference exceeds the safety voltage VW, a short current pulse compensating difference value is interpolated, and monitoring and comparing are continued till thevoltage on the electrodes is less than the safety voltage VW. The nerve stimulator circuit can still realize charge balance in a short time, and the situation that charge is accumulated on the electrodes, consequently, the electrodes are electrolyzed, and nervous tissue is damaged is avoided under the situation of one-way large current stimulation or asymmetric two-way large current stimulation.

Pharmaceutical compositions are provided which include a microRNA pool capable of promoting, stimulating or increasing neuronal differentiation, as well as methods for treating, ameliorating and/or preventing depression or diseases where damage to nervous tissue occurs, such as neurological diseases, by means of such microRNA pool.

The present invention provides methods of identifying markers indicative of the risk of developing a neurodevelopmental disorder caused in part by antibody- or autoantibody-mediated damage of neural tissue, including autism spectrum disorder (ASD). The invention further provides methods of diagnosing whether an individual has a neurodevelopmental disorder, including an ASD, and methods for determining the risk that a mother's future offspring will develop an a neurodevelopmental disorder, including an ASD.

Described is a low voltage, pulsed electrical stimulation device (bioelectric stimulator associated with electrodes) for controlling expression of S100 protein(s) by cellular tissues. The bioelectric stimulator is useful in methods to treat a subject suffering from bladder, heart, and/or nerve tissue damage.

The present invention relates to new inhibitors of the nucleic enzyme poly(adenosine 5′-diphospho-ribose) polymerase [“poly(ADP-ribose) polymerase” or “PARP”, which is also sometimes called “PARS” for poly(ADP-ribose) synthetase]. More particularly, the invention relates to the use of PARP inhibitors to prevent and/or treat tissue damage resulting from cell damage or death due to necrosis or apoptosis; neural tissue damage resulting from ischemia and reperfusion injury; neurological disorders and neurodegenerative diseases; to prevent or treat vascular stroke; to treat or prevent cardiovascular disorders; to treat other conditions and/or disorders such as age-related macular degeneration, AIDS and other immune senescence diseases, arthritis, atherosclerosis, cachexia, cancer, degenerative diseases of skeletal muscle involving replicative senescence, diabetes, head trauma, immune senescence, inflammatory bowel disorders (such as colitis and Crohn's disease), muscular dystrophy, osteoarthritis, osteoporosis, chronic and acute pain (such as neuropathic pain), renal failure, retinal ischemia, septic shock (such as endotoxic shock), and skin aging; to extend the lifespan and proliferative capacity of cells; to alter gene expression of senescent cells; or to radiosensitize hypoxic tumor cells.